GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Important distinction between Kirin and GTC:

Kirin is seeking to produce polyclonal (not monoclonal) antibodies from bovine serum, not from milk. Unlike milk, animal serum is a rather awkward vehicle for developing a commercial drug.

I consider Kirin pretty far down on the list of competitors to be concerned about as a GTC investor.

p.s. Thanks for posting the Post article.